Search Results - matthew+rettig

1 Results Sort By:
2017-094: Inhibitors of the N-Terminal Domain of the Androgen Receptor
SUMMARYUCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.BACKGROUNDProstate...
Published: 7/20/2026   |   Updated: 12/2/2021   |   Inventor(s): Matthew Rettig, Michael Jung
Keywords(s):  
Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)